WILGO research guide

CJC-1295 + IPA

GHRH analogue + growth-hormone secretagogue

Current source listing$70Current listing — $70

Current pricing/options were checked against the linked source catalog. Availability and pricing can change. This page does not provide dosing or human-use instructions. Clicking the BUY button will take you to Calibrated Labs, and off this site.

Research-use context: “What it is used for” below means what scientists and clinical researchers have investigated—not an instruction or recommendation for personal use.

What researchers study

CJC-1295 is a long-acting growth-hormone-releasing hormone analogue, while ipamorelin is a selective growth-hormone secretagogue. Researchers study the pair for effects on GH/IGF-1 signaling, body composition, recovery and muscle biology.

Potential side effects & unknowns

Human data for the combination itself are limited. CJC-1295 studies increased GH and IGF-1 and reported no serious adverse reactions in small early trials, but GH/IGF-1 stimulation can plausibly affect glucose handling, fluid retention, joint symptoms and other endocrine pathways.

Research highlight

Controlled human studies of CJC-1295 showed sustained increases in GH and IGF-1 after dosing. Evidence for the specific CJC-1295/ipamorelin combination is much thinner and includes preclinical rather than strong human outcome studies.

RESEARCH REFERENCE

Continue with the WILGO Research Library

The previously embedded third-party video is no longer available for off-site embedding. WILGO has removed it and retained the page's written research summary, references, and source information.

VIEW RESEARCH LIBRARY

Research references

PubMed: CJC-1295 human study ↗ PubMed: ipamorelin selectivity ↗

Looking for CJC-1295 + IPA?

Follow the tracked WILGO product link to see current inventory, exact product specifications and checkout pricing.

View Current Product →